NasdaqCM:IMTXBiotechs
Is Immatics’ 2025 Loss and PRAME Pipeline Push Altering The Investment Case For Immatics (IMTX)?
Immatics N.V. has reported full-year 2025 results, swinging to a net loss of €196.45 million and a basic loss per share of €1.61 from continuing operations, while also outlining progress across its PRAME-targeting cell therapy pipeline.
Beyond the headline loss, the company’s push to advance anzu-cel toward potential approval and expand PRAME programs like IMA203CD8 and IMA402 highlights an intensifying focus on PRAME as a central therapeutic axis across multiple tumor types.
We will now...